↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Karvonen AL) "

Sökning: WFRF:(Karvonen AL)

Resultat 1-4 av 4

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Pinkney, T, et al. (författare) The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit 2017 Ingår i: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. - : Wiley. - 1463-1318 .- 1462-8910. ; 19:8, s. O296-O311 Tidskriftsartikel (refereegranskat)
2.	Pinkney, T, et al. (författare) An international assessment of the adoption of enhanced recovery after surgery (ERAS®) principles across colorectal units in 2019-2020 2021 Ingår i: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. - : Wiley. - 1463-1318 .- 1462-8910. ; 23:11, s. 2980-2987 Tidskriftsartikel (refereegranskat)
3.	Stengaard-Pedersen, K, et al. (författare) Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing 2004 Ingår i: Rheumatology. - : Oxford University Press (OUP). - 1462-0332 .- 1460-2172. ; 43:5, s. 592-595 Tidskriftsartikel (refereegranskat)abstract Objectives. The primary objective was to demonstrate equivalence between a.m. and p.m. dosing of celecoxib 200 mg q.d. An equivalence assessment of q.d. vs b.i.d. dosing was a secondary objective. Methods. In this randomized, double-blind study, patients with symptomatic osteoarthritis of the knee or hip were randomized to receive celecoxib 200 mg q.d. a.m., celecoxib 200 mg q.d. p.m. or celecoxib 100 mg b.i.d. The primary outcome variable, measured at week 12 on a 0- to 10-point integrated scale, was patient satisfaction-assessment (pain relief, walking/bending, and willingness to continue medication). Equivalence was declared if the 95% confidence interval (CI) of the difference (a.m. q.d. vs p.m. q.d., b.i.d. vs q.d.) fell within the interval of -2 to +2. Results. A total of 697 patients were enrolled in this trial. For the a.m. vs p.m. comparison, the 95% CIs were within the prespecified equivalence criteria for all three measures of patient satisfaction: pain relief, mean -0.2, 95% CI -0.53 to 0.68; ability to walk and bend, mean -0.2, 95% CI -0.54 to 0.64; willingness to continue medication, mean -0.7, 95% CI -0.98 to 0.49. The 95% CIs for the q.d. vs b.i.d. comparison were also within the -2 to +2 interval. Conclusion. Regardless of the time of day at which celecoxib 200 mg q.d. is administered, patients are equally satisfied with the pain relief, ability to walk and bend, and willingness to continue medication.
4.	Suomela, S, et al. (författare) HCR, a candidate gene for psoriasis, is expressed differently in psoriasis and other hyperproliferative skin disorders and is downregulated by interferon-gamma in keratinocytes 2003 Ingår i: The Journal of investigative dermatology. - : Elsevier BV. - 0022-202X. ; 121:6, s. 1360-1364 Tidskriftsartikel (refereegranskat)

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-4 av 4

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (4)

Typ av innehåll: refereegranskat (4)

Författare/redaktör: Rossi, E. (2); Sanchez, J. (2); Wang, X. (2); Davies, E. (2); Alonso, J. (2); Abraham-Nordling, M (2); visa fler...; Garcia-Granero, E (2); Golda, T (2); Mikalauskas, S (2); Perry, R (2); Patel, P. (2); Sharma, A (2); Yamamoto, T. (2); Strupas, K (2); Leventoglu, S (2); Nepogodiev, D (2); Pata, F (2); Smart, N (2); Spinelli, A (2); Sokolov, M (2); Martinek, L (2); Cotte, E (2); Glehen, O (2); Hanly, A (2); Winter, D (2); Zmora, O (2); Bianco, F (2); Muratore, A (2); Belli, A (2); Scabini, S (2); La Torre, F (2); Mingoli, A (2); Konsten, J (2); Barisic, G (2); Krivokapic, Z (2); Kenic, M (2); Escartin, J (2); Frasson, M (2); Pellino, G (2); Tezas, S (2); Velchuru, V (2); Khan, J (2); Bhangu, A (2); Raymond, T (2); Singh, B (2); Branagan, G (2); Oshowo, A (2); Nygren, J (2); COSTA, S (2); Aslam, M. (2); visa färre...

Lärosäte: Karolinska Institutet (3); Lunds universitet (2); Uppsala universitet (1)

Språk: Engelska (4)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy